Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Alfred Burger Award In Medicinal Chemistry: Richard D. DiMarchi
by Linda Wang
January 4, 2016
| A version of this story appeared in
Volume 94, Issue 1
Sponsor: Gilead Sciences
Citation: For the discovery of Humalog and the development of Forteo and rGlucagon. He pioneered the field of chemical biotechnology and mixed peptide agonists for the treatment of metabolic diseases.
Current position: Standiford H. Cox Distinguished Professor of Chemistry, and Linda & Jack Gill Chair in Biomolecular Sciences, Indiana University
Education: B.S., chemistry, Florida Atlantic University; Ph.D., biochemistry, Indiana University
DiMarchi on his biggest research challenge:“The overwhelming perspective that macromolecules were not ‘real’ drugs, largely because they were not oral and did not fit the perspective of more senior chemists trained in classical small-molecule medicinal chemistry.”
What his colleagues say:“Richard is readily recognized for the discovery of Humalog, the first human insulin analog approved for human use that was made using recombinant DNA. He subsequently contributed to the development of glucagon for low blood sugar and Forteo for osteoporosis, meeting the needs of millions of patients with endocrine diseases. His most recent work with glucagon-based mixed agonists for treatment of obesity has received global recognition.”—James P. Reilly, Indiana University
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X